echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Straight to the point! On January 10, 5 listed companies were investigated by institutions, including two pharmaceutical companies

    Straight to the point! On January 10, 5 listed companies were investigated by institutions, including two pharmaceutical companies

    • Last Update: 2023-02-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the statistics of the Oriental Fortune Network Data Center, on January 10, 2023, a total of 5 listed companies were surveyed by institutions, and from the perspective of the number of reception institutions, the company with the highest institutional attention was Xingrui Technology, with a total of 93 institutional surveys, and Shenglu Communications
    was surveyed by more than 20 institutions.

     
    The industries of the above five listed companies that have been concerned by institutions mainly involve science and technology, communications, medicine, etc
    .
    Among them, in the field of medicine, Qianhong Pharmaceutical and Jingjing Pharmaceutical, two pharmaceutical companies, have been investigated
    by institutions.

     
    Straight to the point! On January 10, 5 listed companies were investigated by institutions, including two pharmaceutical companies (Image source: Pharmaceutical Network)
     
    Qianhong Pharmaceutical: Investigated by 8 institutions
     
    On January 10, Qianhong Pharmaceutical received a total of 8 institutional surveys, including three major securities companies such as Ping An Securities, Orient Securities and Everbright Securities, as well as Liuhe Investment and Huisheng Fund
    .

     
    According to the data, Qianhong Pharmaceutical specializes in the research and development, production and sales of biopharmaceuticals, and the company is the head production and operation enterprise of protease and polysaccharide drugs, and is also one of the few domestic pharmaceutical manufacturers covering the whole industry chain of heparin
    .

     
    In the interactive session of institutional research on the 10th, the company said that the overall growth rate of global heparin APIs and preparation products tends to be stable, but in the cycle of high incidence of epidemic and respiratory diseases, the sales of heparin series products in the domestic market will remain at a certain high level
    .

     
    On the news, Qianhong Pharmaceutical announced on the evening of January 6 that it will jointly invest with Makihara to establish a joint venture company "Henan Qianmu Biotechnology Co.
    , Ltd.
    ", which aims to build a biopharmaceutical base for the comprehensive utilization of pig by-products, and produce related products
    including but not limited to crude heparin sodium, heparin sodium and low molecular weight heparin sodium APIs and preparations.

     
    This new initiative has also attracted the attention of institutions, the company said in the institutional survey that the cooperation project with Makihara Co.
    , Ltd.
    is based on the company's years of deep cultivation in the field of heparin series of resource-dependent biochemical drugs, the project covers the whole industrial chain from crude heparin products to API products to preparation products, the first phase of construction is planned to be completed and put into production
    in 2024.
    In the future, the heparin series products of the joint venture will enhance the expected value of the international high-end market and help the benign intensive development
    of the heparin industry.

     
    In addition, the institution also paid attention to the company's judgment on the future trend of heparin prices, the future small intestine bargaining mechanism of Qianmu Company, the centralized procurement of the company's low molecular weight heparin preparations, the company's current innovative drug pipeline and research and development progress, and the company's investment projects in Zhongxiang, Hubei Province
    .

     
    Among them, in terms of innovative drug R&D pipeline, the company said that in the field of small molecule targeted anti-tumor drugs, the first-class new drug QHRD107 has completed phase I clinical trials and is about to enter phase II clinical trials; A new class of QHRD110 has completed Phase IA clinical trials
    in Australia.
    In the field of macromolecular protein genetic engineering drugs, the company's first-class new drug QHRD106 introduced from Japan has completed I.
    a clinical trials, improved new drug long-acting growth hormone QHRD211 has completed phase I clinical trials, and follow-up antibody drug research and development will enter clinical research
    within one to two years.
    The company strives to accelerate the research and development process of new drugs, in order to realize the transformation
    from clinical laboratory to industrial results as soon as possible.

     
    As of the close on January 10, Qianhong Pharmaceutical closed at 6.
    36 yuan, down 1.
    55%, with a turnover rate of 2.
    61%, a volume of 240,900 lots and a turnover of 154 million yuan
    .

     
    In terms of capital flow, the main net inflow of the stock in the past 5 days was -34.
    8617 million, accounting for -3.
    53%.

    The net inflow of funds in the past 10 days was -14.
    2794 million, accounting for -0.
    54%
    of the net.

     
    Essence Pharmaceutical: Received the attention of 1 institution
     
    Jinghua Pharmaceutical received Huiwei Investment Management (Shanghai) Co.
    , Ltd.
    on January 10, which mainly investigated the company's recent production and sales of major varieties and the company's long-term development strategy
    .

     
    According to the data, the main business of Jingjing Pharmaceutical is the research and development, production and sales of traditional Chinese proprietary medicine preparations, APIs and pharmaceutical intermediates, chemical pharmaceutical intermediates, Chinese medicinal materials and Chinese medicine pieces, biopharmaceuticals, etc.
    , and has formed three major sectors
    : Chinese proprietary medicine preparations and Chinese medicine pieces, chemical APIs and pharmaceutical intermediates, biopharmaceuticals and R&D.

     
    The company's varieties have outstanding advantages, the main varieties include Wang's Baochi Pill, Ji Desheng Snake Tablets, Da Chai Hu Granules, Zheng Chai Hu Drink Granules, Golden Buckwheat Cereal, etc
    .

     
    In terms of research and development, the company also has advantages, involving the in-depth secondary development
    of classic proprietary Chinese medicines such as betatinib, a class 1.
    1 targeted anti-tumor new drug, an innovative biological drug anti-VEGFR-2, an anti-PD-L1 fully human monoclonal antibody, a class 1 new drug rHSA/GCSF for injection, as well as large-scale evidence-based medical research on Wang's Baochi Pill and Ji Desheng Snake Tablets.

     
    According to the third quarter report of 2022, Jinghua Pharmaceutical's main revenue reached 1.
    175 billion yuan, a year-on-year increase of 21.
    26%; The net profit attributable to the parent was 169 million yuan, a year-on-year increase of 31.
    52%.


     
    As of the close on January 10, Jingjing Pharmaceutical closed at 12.
    21 yuan, down 0.
    41%, with a turnover rate of 1.
    76%, a volume of 142,500 lots and a turnover of 174 million yuan
    .

     
    In terms of capital flow, the main net inflow of the stock in the past 5 days was -58.
    2627 million, accounting for -7.
    21%.

    The net inflow of funds in the past 10 days was -163 million, accounting for -6.
    15%.


     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.